629 related articles for article (PubMed ID: 16889573)
1. Markers of inflammation and atherosclerosis in Egyptian patients with systemic lupus erythematosus.
Sabry AA; Elbasyouni SR; Kalil AM; Abdel-Rahim M; Mohsen T; Sleem A
Nephrology (Carlton); 2006 Aug; 11(4):329-35. PubMed ID: 16889573
[TBL] [Abstract][Full Text] [Related]
2. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus.
Mahmoud RA; El-Gendi HI; Ahmed HH
Clin Biochem; 2005 Feb; 38(2):134-41. PubMed ID: 15642275
[TBL] [Abstract][Full Text] [Related]
3. Intercellular adhesion molecules in systemic lupus erythematosus patients with lupus nephritis.
Sabry A; Sheashaa H; El-Husseini A; El-Dahshan K; Abdel-Rahim M; Elbasyouni SR
Clin Rheumatol; 2007 Nov; 26(11):1819-23. PubMed ID: 17340048
[TBL] [Abstract][Full Text] [Related]
4. [Proinflammatory cytokines in inactive lupus erythematosus patients].
Lesiak A; Sysa-Jedrzejowska A; Narbutt J; Lukamowicz J; Robak E; Wozniacka A
Przegl Lek; 2005; 62(9):838-42. PubMed ID: 16541713
[TBL] [Abstract][Full Text] [Related]
5. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus.
Svenungsson E; Gunnarsson I; Fei GZ; Lundberg IE; Klareskog L; Frostegård J
Arthritis Rheum; 2003 Sep; 48(9):2533-40. PubMed ID: 13130473
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor induced adhesion molecule serum concentrations in Henoch-Schönlein purpura and pediatric systemic lupus erythematosus.
Gattorno M; Vignola S; Barbano G; Sormani MP; Sabatini F; Buoncompagni A; Picco P; Pistoia V
J Rheumatol; 2000 Sep; 27(9):2251-5. PubMed ID: 10990243
[TBL] [Abstract][Full Text] [Related]
7. Subclinical disease activity in systemic lupus erythematosus: immunoinflammatory markers do not normalize in clinical remission.
Wais T; Fierz W; Stoll T; Villiger PM
J Rheumatol; 2003 Oct; 30(10):2133-9. PubMed ID: 14528506
[TBL] [Abstract][Full Text] [Related]
8. Metabolic syndrome is associated with increased arterial stiffness and biomarkers of subclinical atherosclerosis in patients with systemic lupus erythematosus.
Sabio JM; Vargas-Hitos J; Zamora-Pasadas M; Mediavilla JD; Navarrete N; Ramirez A; Hidalgo-Tenorio C; Jáimez L; Martín J; Jiménez-Alonso J;
J Rheumatol; 2009 Oct; 36(10):2204-11. PubMed ID: 19723903
[TBL] [Abstract][Full Text] [Related]
9. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors.
Asanuma Y; Chung CP; Oeser A; Shintani A; Stanley E; Raggi P; Stein CM
J Rheumatol; 2006 Mar; 33(3):539-45. PubMed ID: 16463434
[TBL] [Abstract][Full Text] [Related]
10. [Rheumatoid arthritis, inflammation, and atherosclerosis].
Hürlimann D; Enseleit F; Ruschitzka F
Herz; 2004 Dec; 29(8):760-8. PubMed ID: 15599672
[TBL] [Abstract][Full Text] [Related]
11. Relationship of oncogenes (sFas, Bcl-2) and cytokines (IL-10, alfa-TNF) with the activity of systemic lupus erythematosus.
Miret C; Font J; Molina R; Garcia-Carrasco M; Filella X; Ramos M; Cervera R; Ballesta A; Ingelmo M
Anticancer Res; 2001; 21(4B):3053-9. PubMed ID: 11712810
[TBL] [Abstract][Full Text] [Related]
12. Correlation between levels of TNF-alpha and IL-6 and hematological involvement in SLE Egyptian patients with lupus nephritis.
Sabry A; Elbasyouni SR; Sheashaa HA; Alhusseini AA; Mahmoud K; George SK; Kaleek EA; abo-Zena H; Kalil AM; Mohsen T; Rahim MA; El-samanody AZ
Int Urol Nephrol; 2006; 38(3-4):731-7. PubMed ID: 17260180
[TBL] [Abstract][Full Text] [Related]
13. Association of interferon gamma, tumor necrosis factor alpha and interleukin 6 serum levels with systemic lupus erythematosus activity.
Robak E; Sysa-Jedrzejewska A; Dziankowska B; Torzecka D; Chojnowski K; Robak T
Arch Immunol Ther Exp (Warsz); 1998; 46(6):375-80. PubMed ID: 9883317
[TBL] [Abstract][Full Text] [Related]
14. Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus.
Lub-de Hooge MN; de Vries EG; de Jong S; Bijl M
Ann Rheum Dis; 2005 Jun; 64(6):854-8. PubMed ID: 15564310
[TBL] [Abstract][Full Text] [Related]
15. Plasma interleukin-6 and tumor necrosis factor-alpha can predict coronary endothelial dysfunction in hypertensive patients.
Naya M; Tsukamoto T; Morita K; Katoh C; Furumoto T; Fujii S; Tamaki N; Tsutsui H
Hypertens Res; 2007 Jun; 30(6):541-8. PubMed ID: 17664858
[TBL] [Abstract][Full Text] [Related]
16. Insulin resistance is related with oxidative stress in systemic lupus erythematosus.
Koca SS; Karaca I; Yavuzkir MF; Dağli N; Ozgen M; Ustündağ B; Işik A
Anadolu Kardiyol Derg; 2009 Feb; 9(1):23-8. PubMed ID: 19196569
[TBL] [Abstract][Full Text] [Related]
17. The Tie2 receptor antagonist angiopoietin 2 facilitates vascular inflammation in systemic lupus erythematosus.
Kümpers P; David S; Haubitz M; Hellpap J; Horn R; Bröcker V; Schiffer M; Haller H; Witte T
Ann Rheum Dis; 2009 Oct; 68(10):1638-43. PubMed ID: 18930996
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory mechanisms affecting the lipid profile in patients with systemic lupus erythematosus.
Chung CP; Oeser A; Solus J; Avalos I; Gebretsadik T; Shintani A; Linton MF; Fazio S; Stein CM
J Rheumatol; 2007 Sep; 34(9):1849-54. PubMed ID: 17659756
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of risk factors that contribute to high prevalence of premature atherosclerosis in Chinese premenopausal systemic lupus erythematosus patients.
Zhang CY; Lu LJ; Li FH; Li HL; Gu YY; Chen SL; Bao CD
J Clin Rheumatol; 2009 Apr; 15(3):111-6. PubMed ID: 19300290
[TBL] [Abstract][Full Text] [Related]
20. Expression of Fcgamma and complement receptors on peripheral blood monocytes in systemic lupus erythematosus and rheumatoid arthritis.
Hepburn AL; Mason JC; Davies KA
Rheumatology (Oxford); 2004 May; 43(5):547-54. PubMed ID: 14747618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
